The aims of this study were to identify the differences in (1) serum markers, synovial indicators and pathology results and (2) treatment outcomes following two-stage exchange arthroplasty between patients with or without inflammatory diseases.
Patients and Methods
A retrospective review of 182 prosthetic joint infection patients who underwent two-stage exchanged arthroplasty from 2014 to 2017 was conducted. PJI was diagnosed by using the MSIS criteria. Serum biomarkers, synovial fluid, organism and pathology results at the time of the PJI diagnosis and reimplantation were reviewed and compared between patients with or without inflammatory diseases. Treatment success was defined according to the Delphi consensus criteria; Kaplan-Meier survivorship curves of the patients were generated and compared. The mean clinical follow-up duration was 33.9 months (15.9 to 51.9) in the no inflammatory group and 35.5 months (16.2 to 54.8) in the inflammatory group.
Results
There was no difference in the biomarkers, pathology results or organism profile at the time of the PJI diagnosis. Regarding reimplantation, the patients with inflammatory diseases had a higher serum erythrocyte sedimentation rate and C-reactive protein, interleukin-6, and fibrinogen values than those without inflammatory diseases. However, there was no difference in the synovial white blood cell counts between groups. The total treatment success rate was 91.3% (92% for individuals with inflammatory diseases and 91.2% for the controls). The survivorship of the inflammatory disease group was comparable with that of the control group.
Conclusion
Two-stage exchange arthroplasty is a viable treatment option for PJIs with inflammatory diseases. Individuals with PJIs and inflammatory diseases have higher serum inflammatory biomarker levels at reimplantation, which may make determining the timing of reimplantation difficult. In contrast, synovial analysis may be more reliable.
Background
Inflammatory diseases are chronic systemic autoimmune diseases that mainly include rheumatoid arthritis (RA), psoriatic arthritis (PSA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), and systemic lupus erythematosus (SLE). The prevalence of inflammatory diseases is rarely low, with a rate ranging from 0.05-1% in the general population 1 . Although several studies have suggested a decreasing trend in the occurrence of inflammatory diseases 2,3 , there are a considerable number of individuals with inflammatory diseases with severe arthritis who are candidates for total joint arthroplasty (TJA) 4 .
Prosthetic joint infection (PJI) is a devastating complication that develops after TJA with an incidence of 1-3% following primary TJA and 3-5% following revision TJA 5 − 9 , which leads to a tremendous burden for individual patients as well as the global health care industry 10 . Many studies have attempted to identify potential risk factors for PJI. For example, individuals with a medical history of an inflammatory disease have been shown to be independently associated with more than 4 times as many subsequent PJIs than those with osteoarthritis due to the long-term use of disease-modifying anti-rheumatic drugs (DMARDs) 11 , biological drugs and corticosteroids 12 − 17 .
The management of PJI remains challenging. Two-stage exchange arthroplasty remains the "gold standard" for chronic PJI in North America and East Asia 18, 19 , with success rates ranging from 65 to 100% 20 . Due to the low incidence of inflammatory diseases, there are limited data on the outcomes following two-stage exchange arthroplasty for individuals with PJI and inflammatory diseases. In the clinic, surgeons frequently consider patients with inflammatory diseases to have inferior outcomes than those without inflammatory diseases. However, to the best of our knowledge, no study has been conducted to compare the outcomes between patients with or without inflammatory diseases. Additionally, whether the current thresholds of inflammatory biomarkers can be applied in patients with inflammatory diseases at PJI diagnosis remains unknown.
In this study, we investigated (1) whether there were any differences in the serum indicators, cultures and pathology results between patients with and without inflammatory diseases and (2) whether patients with inflammatory diseases have a poor prognosis after two-stage revision surgeries compared to those without inflammatory diseases.
Methods

Patients
We retrospectively reviewed the database of our hospital to identify all patients who underwent two-stage revision for PJI after total knee arthroplasty (TKA) or total hip arthroplasty (THA). A total of 226 patients (228 joints) underwent two-stage revision between 2014 and 2017, of which 28 patients (12.3%) suffered from inflammatory diseases (including rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis).
The diagnoses of inflammatory diseases were made on the basis of the Assessment of SpondyloArthritis International Society's criteria for AS 21 , 2010 Rheumatoid Arthritis Classification Criteria for RA 22 , and criteria proposed by Taylor for psoriatic arthritis 23 . All inflammatory disease patients underwent medical therapy involving DMARDs, biological drugs or corticosteroids in the rheumatology department, and the inflammatory diseases were not active or showed low levels of activity before surgery.
In the no inflammatory disease group, 13 patients were excluded because they did not meet the Musculoskeletal Infection Society (MSIS) criteria 24 for PJI, 12 patients were excluded because they did not undergo two-stage revision, and 15 patients were excluded due to a follow-up period of less than 1 year. In the inflammatory disease group, 3 patients who did not meet the MSIS criteria for PJI were excluded, and 1 patient was excluded because he or she did not undergo two-stage revision. Therefore, a total of 182 patients (77 knees and 107 hips) were included in the final analyses; of these, 24 patients (8 knees and 17 hips) were diagnosed with inflammatory diseases, including 12 with rheumatoid arthritis, 8 with ankylosing spondylitis and 4 with psoriatic arthritis (Fig. 2 ).
The medical records were reviewed manually in detail to determine whether there were any differences between patients with and without inflammatory diseases in the demographic data (sex, age, body mass index [BMI], and type of joint [knees or hips]) or American Society of Anesthesiologists (ASA) score. We included comorbidities as defined by the international consensus on PJI 24 and other risk factors, including hepatitis and cardiovascular disease 25 . The serologic test results (including erythrocyte sedimentation rate [ESR], C-reactive protein [CRP], interleukin-6 [IL-6], fibrinogen, d-dimer), pathology results, and organism culture test results were compared between the two groups at the time of resection and reimplantation.
Treatment protocol
An institutional standard protocol for two-stage procedures was performed 26 . The timing of implantation was based on the following criteria: no clinical signs of infection, a wellhealed surgical wound, and a declining trend in the inflammatory markers. A period of at least 2 weeks of antibiotic holiday before the second-stage surgery was stipulated. The median interval between the 1st stage and 2nd stage was 126.00 (25.00 to 1203.00) days in the no inflammatory disease group and 126.00 (37.00 to 391.00) days in the inflammatory disease group (P = 0.998).
Definition of the endpoints and treatment success
Primary endpoints for this study were defined as follows: 1. spacer exchange because of infection recurrence; 2. Reinfection (according to MSIS criteria) after reimplantation; 3.
long-term antibiotic suppression at the time of the last follow-up; and 4. death related to PJI.
We determined treatment success using the following Delphi consensus criteria 27,28 : 1. infection eradication, characterized by a healed wound without fistula, drainage, pain, or infection recurrence caused by the same organism strain; 2. no subsequent surgical intervention for infection after reimplantation surgery; and 3. no occurrence of PJI-related mortality.
Statistical analysis
All of the statistical analyses were performed with the statistical software package R (http://www.R-project.org, The R Foundation). The categorical data were summarized as the absolute value and percentage. The continuous data are presented as the mean and standard deviation (SD). The demographic and clinical characteristics were compared between groups with the Student's t-test if the data were normally distributed; if the data were not normally distributed, the Mann-Whitney test was used for continuous variables and the chi-square test or Fisher's exact test was used for categorical variables. Kaplan-Meier survivorship curves with treatment failure as an endpoint were generated.
Differences in survivorship between patients with or without inflammatory diseases were assessed using the log-rank test. A retrospective power analysis was calculated based on the 5-year survival rates. A p-value less than 0.05 was considered significant.
Results
General Information
The patient characteristics are shown in Table 1 . There was no significant difference in age, sex, ASA, type of surgery, joint function score, or smoking habits between the inflammatory disease and no inflammatory disease groups. Interestingly, patients in the inflammatory disease group had a higher prevalence of renal disease than the control group (20.00% VS 2.52%, p = 0.003), while there was no significant difference in the other relevant risk factors according to our analysis. More alcohol abusers were found in the inflammatory diseases group (28.00% VS 8.18%, p = 0.009), indicating the need for more effective management. 
Lab, Microbiology and Pathology Tests at Spacer Insertion
We retrospectively collected and analysed all data from the database on the lab, culture and pathology tests for both groups at the time of spacer insertion. The results are shown in 25.32 pg/ml, respectively, in the inflammatory disease group. The mean ESR, fibrinogen and d-dimer levels were 26.00 mm/hr, 4.12 g/l and 3.02 ug/ml, respectively. However, the synovial WBC count showed satisfactory consistency between the two groups. The mean synovial WBC count was 1467.14*10 9 /ml in the no inflammatory disease group and 1279.33*10 9 /ml in the inflammatory disease group (p = 0.839). The culture positive rate was low at the time of reimplantation. Only 1 case of gram-negative bacillus and 1 case of MRSA were identified in the inflammatory diseases group. The positive pathology rate was 18.95% in the no inflammatory disease group and 10.52% in the inflammatory disease group (p = 0.570). (95% CI, 69.23 to 100.00%) at 5 years ( Fig. 1 ). No significant difference was found between the two groups in the probability of survival (p = 0.89).
Table 3 Lab tests and culture results among patients with and without inflammatory diseases at reimplantation
Discussion
Prosthetic joint infection (PJI) is a devastating complication, and inflammatory diseases have been reported to be an important risk factor for PJI in many articles 11 − 14 indicating that the MSIS criteria are also optional standards for diagnosing inflammatory disease patients. The average fibrinogen levels in both groups were higher than 4.10 g/l, which is in accordance with the results reported by LI R et al 29 , suggesting that fibrinogen is a helpful indicator for both patients with and without inflammatory diseases. Coagulasenegative staphylococci were the most common organisms in the inflammatory disease group in our research, while no significant difference was found in the type or ratio of microorganisms. An excessive focus on the elevation of the inflammatory indictors caused by the inflammatory diseases was shown to be unnecessary, as the infection activated the immune system and led to even higher levels of the biomarkers in individuals with wellcontrolled inflammatory diseases.
At the reimplantation stage, there is no gold standard for the diagnosis of PJI, and the MSIS criteria are considered to have low sensitivity because of long-term antibiotic suppression 32 . However, we found a significant difference between the no inflammatory disease and inflammatory disease groups in the serum markers. The average CRP and IL-6 levels were clearly elevated, even though the inflammatory diseases of all patients included in the analysis showed low levels of activity. The synovial WBC count showed good consistency between the two groups and was less affected by the immune changes caused by the inflammatory diseases. Many articles have explained the elevation in serum and synovial IL-6, ESR, and CRP in patients with inflammatory diseases 33, 34 , causing ultrahigh sensitivity in diagnosing PJI before insertion. Significant differences in the inflammatory indicators in the inflammatory disease group were observed in our research, which may sometimes mislead clinical doctors and make it difficult to distinguish inflammatory disease related PJIs using serum biomarkers alone. In addition, fibrinogen recommended by LI R et al 29 failed to distinguish inflammatory diseases and PJIs at reimplantation due to its elevation in both inflammatory diseases and PJIs. However, synovial fluid is a local immune response that is less influenced by inflammatory diseases.
The recommended marker is the synovial WBC count at the time of reimplantation because of its good agreement between patients with and without inflammatory diseases.
XIE K et al 31 reported that the synovial IL-6 level showed higher sensitivity and specificity than the serum IL-6 level in diagnosing PJI, but more research is required to determine whether the synovial IL-6 level is less affected by inflammatory diseases. More research is needed to identify the thresholds of synovial indicators for diagnosing PJIs in individuals with inflammatory diseases and PJIs.
Two-stage revision is widely reported to be a viable procedure for prosthetic joint infection 10, 35, 36 , and patients with inflammatory diseases suffer from a higher risk of infections than those without inflammatory diseases. However, we found that inflammatory diseases and PJIs can be resolved, and the survivorship in individuals with Written informed consent was obtained from all participants.
Consent for publication
Not applicable.
Availability of data and materials
We do not wish to share our data, because some of the patient's data regarding individual privacy, and according to the policy of our hospital, the data could not be shared with others without permission. Flowchart of details of patients underwent two stage reimplantation
Figures
